Sergio Sosa-Estani1, Elsa Leonor Segura. 1. Centro Nacional de Diagnóstico e Investigación de Endemo-epidemias (CeNDIE), Ministerio de Salud y Ambiente, Buenos Aires, Argentina. ssosa@msal.gov.ar
Abstract
PURPOSE OF REVIEW: The aim of this review is to describe knowledge, mainly of the last 15 years, that changed criteria for specific treatment against Trypanosoma cruzi infection. RECENT FINDINGS: Over the past 15 years, there has been an increase in the use of new methodologies to evaluate the efficacy of antiparasitic treatments. These tools showed that the evaluation period for trypanocidal treatment effectiveness could be shortened. Based on the hypothesis that Chagas' cardiomyopathy may indeed be triggered by persistent parasitic infection, it seems plausible that trypanocidal therapy may delay, reduce or prevent the progression to the disease. SUMMARY: Based on the present knowledge, we can assume that every patient infected with Trypanosoma cruzi in the acute phase and in the early chronic phase (i.e. children under 16 years old) must be treated, and adults could be treated. In this area, research priorities should target obtaining new drugs to allow shorter treatments with fewer adverse reactions and improving new tools to confirm cure when patients are treated during the Chronic Phase.
PURPOSE OF REVIEW: The aim of this review is to describe knowledge, mainly of the last 15 years, that changed criteria for specific treatment against Trypanosoma cruzi infection. RECENT FINDINGS: Over the past 15 years, there has been an increase in the use of new methodologies to evaluate the efficacy of antiparasitic treatments. These tools showed that the evaluation period for trypanocidal treatment effectiveness could be shortened. Based on the hypothesis that Chagas' cardiomyopathy may indeed be triggered by persistent parasitic infection, it seems plausible that trypanocidal therapy may delay, reduce or prevent the progression to the disease. SUMMARY: Based on the present knowledge, we can assume that every patient infected with Trypanosoma cruzi in the acute phase and in the early chronic phase (i.e. children under 16 years old) must be treated, and adults could be treated. In this area, research priorities should target obtaining new drugs to allow shorter treatments with fewer adverse reactions and improving new tools to confirm cure when patients are treated during the Chronic Phase.
Authors: C A Barfield; R S Barney; C H Crudder; J L Wilmoth; D S Stevens; S Mora-Garcia; M J Yanovsky; B H Weigl; J Yanovsky Journal: IEEE Trans Biomed Eng Date: 2011-03 Impact factor: 4.538
Authors: Ana Paula Gruendling; Miyoko Massago; Ana Paula M Teston; Wuelton M Monteiro; Edilson N Kaneshima; Silvana M Araújo; Mônica L Gomes; Maria das Graças V Barbosa; Max Jean O Toledo Journal: Am J Trop Med Hyg Date: 2015-05-04 Impact factor: 2.345
Authors: Rubi Gamboa-León; Claudia Ramirez-Gonzalez; Freddy S Pacheco-Tucuch; Matthew O'Shea; Kathryn Rosecrans; Julia Pippitt; Eric Dumonteil; Pierre Buekens Journal: Am J Trop Med Hyg Date: 2014-06-16 Impact factor: 2.345
Authors: Oliver Yun; M Angeles Lima; Tom Ellman; Wilma Chambi; Sandra Castillo; Laurence Flevaud; Paul Roddy; Fernando Parreño; Pedro Albajar Viñas; Pedro Pablo Palma Journal: PLoS Negl Trop Dis Date: 2009-07-07